Report of Foreign Issuer (6-k)
April 29 2020 - 4:33PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2020
Commission File Number: 001-31368
SANOFI
(Translation of
registrants name into English)
54, rue La
Boétie, 75008 Paris, FRANCE
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F
or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If Yes marked, indicate below the file number assigned to the registrant in connection with Rule
12g3-2(b): 82-________
In April 2020, Sanofi issued the press releases attached hereto as Exhibit 99.1, 99.2 and 99.3 which are
incorporated herein by reference.
Exhibit List
|
|
|
Exhibit No.
|
|
Description
|
|
|
Exhibit 99.1
|
|
Press release dated April 28, 2020: Annual General Meeting of April 28, 2020
|
|
|
Exhibit 99.2
|
|
Press release dated April 27, 2020: Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell
lung cancer stopped early due to highly significant improvement in overall survival
|
|
|
Exhibit 99.3
|
|
Press release dated April 27, 2020: Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients
|
2
Exhibit Index
|
|
|
Exhibit No.
|
|
Description
|
|
|
Exhibit 99.1
|
|
Press release dated April 28, 2020: Annual General Meeting of April 28, 2020
|
|
|
Exhibit 99.2
|
|
Press release dated April 27, 2020: Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell
lung cancer stopped early due to highly significant improvement in overall survival
|
|
|
Exhibit 99.3
|
|
Press release dated April 27, 2020: Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients
|
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
Dated: April 29, 2020
|
|
|
|
|
|
SANOFI
|
|
|
|
|
|
By
|
|
/s/ Alexandra Roger
|
|
|
|
|
Name:
|
|
Alexandra Roger
|
|
|
|
|
Title:
|
|
Head of Securities Law and
Capital Markets
|
4
Sanofi (PK) (USOTC:SNYNF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sanofi (PK) (USOTC:SNYNF)
Historical Stock Chart
From Sep 2023 to Sep 2024